본문으로 건너뛰기
← 뒤로

Urine metabolic analysis as a noninvasive method to diagnose prostate cancer.

1/5 보강
Urologic oncology 2026 Vol.44(2) p. 125.e1-125.e10
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
201 patients were included in the study, with a mean age of 67.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Metabolomics can be used to build a useful predictive model for diagnosing prostate cancer from the metabolic profile in urine, using a total of 28 metabolites. Combining metabolites, particularly molecules of glycerophospholipid metabolism, glycolysis, and amino acid metabolism, with clinical variables provides an effective strategy.

Panach-Navarrete J, González-Marrachelli V, Morales-Tatay JM, García-Morata F, Sales-Maicas MÁ, Monleón-Salvado D, Martínez-Jabaloyas JM

📝 환자 설명용 한 줄

[OBJECTIVES] This study used urine NMR spectroscopy to define a potential metabolic profile indicating presence of prostate cancer, which could be a useful noninvasive method for diagnosis of this neo

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • Sensitivity 89%

이 논문을 인용하기

↓ .bib ↓ .ris
APA Panach-Navarrete J, González-Marrachelli V, et al. (2026). Urine metabolic analysis as a noninvasive method to diagnose prostate cancer.. Urologic oncology, 44(2), 125.e1-125.e10. https://doi.org/10.1016/j.urolonc.2025.10.015
MLA Panach-Navarrete J, et al.. "Urine metabolic analysis as a noninvasive method to diagnose prostate cancer.." Urologic oncology, vol. 44, no. 2, 2026, pp. 125.e1-125.e10.
PMID 41238477

Abstract

[OBJECTIVES] This study used urine NMR spectroscopy to define a potential metabolic profile indicating presence of prostate cancer, which could be a useful noninvasive method for diagnosis of this neoplasia.

[METHODS] Urine samples were obtained from patients undergoing transrectal prostate biopsy after prostate massage. Patients were classified as diseased if cancerous tissue was obtained from biopsy histology, and all spectra were acquired using a Bruker Avance III DRX 600 spectrometer. Univariate and multivariate analyses were performed with metabolites and clinical variables with the objective of predicting tumor presence.

[RESULTS] A total of 201 patients were included in the study, with a mean age of 67.20 ± 7.90 years. Prostate cancer was diagnosed in 107 (53.2%) cases, with a negative result for malignancy in the other 94 (46.8%).Metabolic analysis revealed metabolic pathways such as glycolysis, Krebs cycle, and the metabolism of different amino acids as involved in the presence of prostate cancer. The 28 metabolites detected in urine, together with prostate volume and ultrasound suspicion for tumor, formed a predictive model of prostate cancer in tissue, with an area under the curve (AUC) of 0.89, a sensitivity of 89%, a positive predictive value (PPV) of 82% and a negative predictive value (NPV) of 83%.

[CONCLUSIONS] Metabolomics can be used to build a useful predictive model for diagnosing prostate cancer from the metabolic profile in urine, using a total of 28 metabolites. Combining metabolites, particularly molecules of glycerophospholipid metabolism, glycolysis, and amino acid metabolism, with clinical variables provides an effective strategy.

MeSH Terms

Humans; Male; Prostatic Neoplasms; Aged; Middle Aged; Metabolomics; Magnetic Resonance Spectroscopy; Biomarkers, Tumor

같은 제1저자의 인용 많은 논문 (2)